Table 1.
Activity of PD1/PD-L1 inhibitors alone or in combination with chemotherapy in OC.
| ICI | Target | Phase | N | Indication | RR (%) | PFS (median) | Ref |
|---|---|---|---|---|---|---|---|
| Single agent | |||||||
| Pembrolizumab | PD1 | Ib | 26 | PD-L1 + recurrent OC | 11 | 1.9 mo | Varga et al.20 |
| Avelumab | PD-L1 | Ib | 125 | Recurrent OC | 10 | 1 yr PFS 10% | Disis et al.21 |
| Nivolumab | PD1 | II | 20 | PROC | 15 | 3.5 mo | Hamanishi et al.18 |
| Pembrolizumab | PD1 | II | |||||
| Cohort A | 285 | 1–3 lines TFI 3–12 mo | 7 | 2.1 | |||
| Cohort B | 91 | 4–6 lines TFI > 3 mo | 10 | 2.1 | Matulonis et al.22 | ||
| ICI + chemotherapy | |||||||
| Avelumab versus PLD versus AVE + PLD | PD-L1 | III randomized 1 :1 :1 | 188 | PROC | 4 | 1.9 mo | Pujade-Lauraine et al.28 |
| 190 | 4 | 3.5 mo | |||||
| 188 | 13 | 3.7 mo |
AVE, avelumab; ICI, immune checkpoint inhibitor; OC, ovarian cancer; PD1, Programmed cell death protein 1; PD-L1, programmed death ligand 1; PFS, progression-free survival; PLD, pegylated liposomal doxorubicin; PROC, platinum resistant ovarian cancer; RR, response rate; TFI, treatment free interval.